# US 2020/0393699 A1 · Method and apparatus for limiting growth of eye length

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0393699 A1
- Document ID: US20200393699A1
- Status: Published application
- Kind: A1
- Application number: 17/008,167
- Filed: 2020-08-31
- Published: 2020-12-17
- Earliest claimed: 2008-12-22
- Assignees: The Medical College of Wisconsin, Inc.
- Applicants: The Medical College of Wisconsin, Inc.
- Inventors: Jay Neitz; Maureen Neitz
- Web page: https://patentgrep.com/patent/US20200393699A1

## CPC

- G02C 7/04: Contact lenses for the eyes (disinfection or sterilisation of contact lenses A61L12/00)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G02C 7/02: Lenses; Lens systems {; Methods of designing lenses}
- G02C 7/022: {Ophthalmic lenses having special refractive features achieved by special materials or material structures (G02C7/049 takes precedence)}
- G02C 7/061: {Spectacle lenses with progressively varying focal power}
- G02C 7/10: Filters, e.g. for facilitating adaptation of the eyes to the dark; Sunglasses
- G02C 7/16: Shades; shields; Obturators, e.g. with pinhole, with slot {(G02C5/003 takes precedence)}
- A61B 3/1005: {for measuring distances inside the eye, e.g. thickness of the cornea (A61B3/11 takes precedence)}
- A61B 5/107: Measuring physical dimensions, e.g. size of the entire body or parts thereof
- G02C 2202/24: Myopia progression prevention
- G02C: SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES (trial frames for testing the eyes A61B3/04; goggles or eyeshields not having the same features as spectacles A61F9/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.

## Claims

### Claim at position 1

1-5. (canceled)

### Claim 6

A therapeutic treatment method for preventing, ameliorating, or reversing eye-length-related disorders of a patient, the therapeutic treatment method comprising:
obtaining information representing characteristics of an eye of the patient;
determining, based on the information, whether the patient has or is disposed to an eye-length-related disorder; and
upon determining that the patient has or is disposed to the eye-length-related disorder, providing the patient with a therapeutic device comprising an ophthalmic lens that is configured, upon use by the patient, to cause blurring of images input to an eye of the patient sufficient to reduce a first rate of axial growth of the patient's eye compared to a second rate of growth of the eye,
wherein the second rate of growth is a rate of growth exhibited by the eye equipped with a control lens and causing the blurring includes modifying light passing through the chosen ophthalmic lens to the eye of the patient by any of light scattering, diffraction, and higher order aberrations.

### Claim 7 (depends on 6)

The method of claim 6, wherein said blurring includes reducing an average spatial frequency of the optical image on a retina of the eye of the patient to a value at which a process of eye lengthening is at least temporarily prevented.

### Claim 8 (depends on 6)

The method of claim 6, wherein said modifying light includes introducing optical aberrations at a periphery of a field of vision of the patient while leaving a center of the field of vision of the patient in focus.

### Claim 9 (depends on 6)

The method of claim 6, wherein said causing the blurring includes reducing, with the use of said chosen ophthalmic lens, visual acuity in a peripheral image region of the eye of the patient from 20/20 to a value of visual acuity in the range of about 20/25.

### Claim 10 (depends on 6)

The method of claim 6, comprising maintaining normal non-aberrated vision for the eye of the patient along a direction aligned with an axis of the eye of the patient.

### Claim 11 (depends on 6)

The method of claim 6, wherein the therapeutic device comprises a pair of glasses.

### Claim 12 (depends on 6)

The method of claim 6, wherein therapeutic device comprises contact lenses.

### Claim 13 (depends on 6)

The method of claim 6, wherein the ophthalmic lens comprises a plurality of first elements that produce the blurring, the first elements being selected from the group consisting of:
(i) bumps on a surface of the first ophthalmic lens;
(ii) depressions on the surface of the first ophthalmic lens;
(iii) first translucent inclusions in a first ophthalmic lens material; and
(iv) first transparent inclusions in the first ophthalmic lens material, the first transparent inclusions having a refractive index different from that of the first ophthalmic lens material.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ophthalmic lens in which the first elements are located in a first area of the lens, the ophthalmic lens further comprising a second area surrounded by the first area, said second area being free of the first elements.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first elements are dot-shaped elements.

### Claim 16 (depends on 15)

The method of claim 15, wherein the dot-shaped elements having a non-zero dot density in a range between 0 and 8 dots per mm2.

### Claim 17 (depends on 15)

The method of claim 15, wherein the dot-shaped elements are particles as large as or larger than a wavelength of light.

### Claim 18 (depends on 15)

The method of claim 15, wherein the dot-shaped elements are particles smaller than a wavelength of light.

### Claim 19 (depends on 6)

The method of claim 6, wherein the information is obtained by performing a vision test of the patient.

### Claim 20 (depends on 6)

The method of claim 6, wherein the information is obtained by measuring an axial length of an eye of the patient.

### Claim 21 (depends on 6)

The method of claim 6, wherein the information includes performing at least one of (i) a vision test to reveal myopia, and (ii) measuring an axial length of the eye of the patient.

### Claim 22 (depends on 6)

The method of claim 6, wherein the determining is carried out based on a measurement of a discrepancy between a length of the eye of the patient and a control length of an eye of a similarly aged or sized individuals

### Claim 23 (depends on 22)

The method of claim 22, wherein the therapeutic device is provided to apply a level of blurring proportional to the discrepancy.

### Claim 24 (depends on 22)

The method of claim 22, wherein the therapeutic device is provided to apply a level of blurring inversely related to the discrepancy.

### Claim 25 (depends on 22)

The method of claim 22, wherein the therapeutic device is provided to apply a constant level of blurring over a range of discrepancies.

### Claim 26 (depends on 6)

The method of claim 6, wherein the therapeutic treatment method reduces eye lengthening of a patient relative to an eye with untreated myopia by at least 2 mm over a period of at least five years.

### Claim 27 (depends on 6)

The method of claim 6, wherein implementing said therapeutic treatment method causes reduction of lengthening of the eye of the patient equipped with said ophthalmic lens by between 0.9 microns per day and 1.5 microns per day, as compared with an eye equipped with the control lens.

### Claim 28 (depends on 6)

The method of claim 6, implemented on a child.

### Claim 29 (depends on 6)

The method of claim 6, implemented on a child of age 10 or younger.
